Published in Pharma Investments, Ventures and Law Weekly, December 31st, 2006
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Avi BioPharma.
Report 1: Avi BioPharma, Inc., (AVII) presented data and analysis from four Neugene antisense clinical studies at the second annual meeting of the Oligonucleotide Therapeutics Society at Rockefeller University in New York.
The clinical briefing, titled...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly